Commentary. Telomerase as an anti-cancer target: Current status and future prospects

Anti-Cancer Drug Design

Volumn 14, Issue 4, 1999, Pages 341-347

  Neidle, Stephen ^a   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; RIBONUCLEOPROTEIN; TELOMERASE; ANTISENSE OLIGONUCLEOTIDE; ENZYME INHIBITOR;

CANCER GENETICS; CYTOLOGY; DRUG DNA BINDING; DRUG TARGETING; ENZYME INHIBITION; MOLECULAR BIOLOGY; NOTE; PRIORITY JOURNAL; TELOMERE; TUMOR CELL; ANIMAL; BINDING SITE; DRUG ANTAGONISM; HUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; ENZYME INHIBITORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; TELOMERASE; TELOMERE;

EID: 0033170136     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (60)

1. Bare L.A., Trinh I., Wu S., Devlin J.J. (1998) Identification of a series of potent telomerase inhibitors using a time-resolved fluorescence-based assay. Drug Development Research, 43, 109.
2. Blackburn E.H. (1991) Structure and function of telomeres. Nature, 350, 569.
3. Blasco M.A., Lee H.-W, Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., Greider C.W. (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell, 91, 25.
4. Bodnar A.G., Quellette M., Frolkis M., Holt S.E., Chiu C.-P., Morin G.B., Barley C.B., Shay J.W., Lichtsteiner S., Wright W.E. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science, 379, 349.
5. Bryan T.M., Englezou A., Dalla.-Pozza L., Dunham M.A., Reddel R.R. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Medicine, 3, 1271.
6. Clark G.M., Osborne C.K., Levitt D., Wu R., Kim N.W. (1997) Telomerase activity and survival of patients with Node-positive breast cancer. Journal of the National Cancer Institute, 89, 1874.
7. Counter C.M., Hahn W.C., Wei W., Caddle S.D., Beuersbergen R.I., Lansdorf P.M., Sedivy J.M., Weinberg R.A. (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Cell Biology, 95, 14723.
8. Cuthbert A.P., Bond J., Trott D.A., Gill S., Broni J., Marriott A., Khoudoli G., Parkinson E.K., Cooper C.S., Newbold R.F. (1999) telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. Journal of the National Cancer Institute, 91, 37.
9. Duncan V.E., Ajmani P.S., Hughes J.A. (1998) Cellular delivery is a major obstacle for oligodeoxy nucleotide inhibition of telomerase activity. Anticancer Research, 18, 4105.
10. Fedoroff O.Y, Salazar M., Han H., Chemeris V.V., Kerwin S.M., Hurley L.H. (1998) NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. Biochemistry, 37, 12367.
11. Feng J., Funk W.D., Wang S.-S., Weinrich S.L., Avilion A.A., Chiu C.-P., Adams R.R., Chang E., Allsopp R.C., Yu J., Le S., West M.D., Harley C.B., Andrews W.H., Greider C.W., Villeponteau B. (1995) The RNA component of human telomerase. Science, 269, 1236.
12. Fletcher T.M., Sun D., Salazar M., Hurley L.H. (1998) Effect of secondary structure on human telomerase activity. Biochemistry, 37, 5536.
13. Gomez D.E., Tejera A.M., Olivero O.A. (1998) Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment. Biochemical and Biophysical Research Communications, 246. 107.
14. 2/3 cancer-prone mouse. Cell, 97, 515.
15. Greider C.W. (1999) Telomerase activation one step on the road to cancer? Trends in Genetics, 15, 109.
16. Hamilton S.F., Corey D.R. (1996) Telomerase: anti-cancer target or just a fascinating enzyme? Chemistry and Biology, 3, 863.
17. Hamilton S.E., Pitts A.E., Katipally R.R., Jia X., Rutter J.P., Davies B.A., Shay J.W., Wright W.E., Corey D.R. (1997) Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry, 36, 11873.
18. Hamilton S.E., Simmons C.G., Kathiriya I.S., Corey D.R. (1999) Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chemistry & Biology, 6, 343.
19. Han H., Cliff C.L., Hurley L.H. (1999a) Accelerated assembly of G-quadruplex structures by a small molecule. Biochemistry, 38, 6981.
20. Han H., Hurley L.H., Salazar M. (1999b) A DNA polymerase stop assay for G-quadruplex-interactive compounds. Nucleic Acids Research, 27, 537.
21. Harrison J.G., Frier C., Laurant R., Dennis R., Raney K.D., Balasubramanian S. (1999) Inhibition of human telomerase by PNA-cationic peptide conjugates. Bioorganic & Medicinal Chemistry Letters, 9, 1273.
22. Hiyama E., Hiyama K., Yokoyama T., Matsuura Y, Piatyszek M.A., Shay J.W. (1995) Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Medicine, 1, 249.
23. Izbicka E., Wheelhouse R.T., Raymond R., Davidson K.K., Lawrence R.A., Sun D., Windle B.E., Hurley L.H., Von Hoff D.D. (1999) Effects of cationic phorphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Research, 59, 639.
24. Karlseder J., Broccoli D., Dai Y., Hardy S., de Lange T. (1999) P53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science, 283, 1321.
25. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science, 266, 2011.
26. INK4a inactivation and telomerase activity are required to immortalise human epithelial cells. Nature, 396, 84.
27. Kondo S., Kondo Y., Li G., Silverman R.H., Cowell J.K. (1998) Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene, 16, 3323.
28. Lackey D.B. (1998) A homogeneous chemiluminescent assay for telomerase. Analytical Biochemistry, 263, 57.
29. Lee H.-W., Blasco M.A., Gottlieb G.J., Horner J.W. II, Greider C.W., Depinho R.A. (1998) Essential role of mouse telomerase in highly proliferative organs. Nature, 392, 569.
30. Matthes E., Lehmann C.H. (1999) Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Research, 27, 1152.
31. Melana S.M., Holland J.F., Pogo B.C.-T. (1998) Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clinical Cancer Research, 4, 693.
32. Mergny J.L., Hélène C. (1998) G-quadruplex DNA: a target for drug design. Nature Medicine, 4, 1366.
33. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Lie Q., Bacchetti S., Haber D.A., Weinberg R.A. (1997) HEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 90, 785.
34. Multani A.S., Furlong C., Pathak S. (1998) Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3′-azido-2′-3′-dideoxythymidine. International Journal of Oncology, 13, 923.
35. Naasani I., Seimiya H., Tsuruo T. (1998) Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochemical and Biophysical Research Communications, 249, 391.
36. Niida H., Matsumoto T., Satch H., Shiwa M., Tokutake Y, Foeli Y, Shinkai Y (1998) Severe growth defect in mouse cells lacking the telomerase RNA component. Nature Genetics, 19, 203.
37. O'Reilly M., Teichmann S.A., Rhodes D. (1999) Telomerases. Current Opinion in Structural Biology, 9, 56.
38. Ouellette M.M., Aisner D.L., Savre-Train I., Wrights W.E., Shay J.W. (1999) Telomerase activity does not always imply telomere maintenance. Biochemical and Biophysical Research Communications, 254, 795.
39. Pai R.B., Balakrishna P., Kukhanova M., Dutschman G.E. Guo X., Cheng Y.-C. (1998) Telomerase from human leukemia cells: properties and its interaction with deoxynucleoside analogues. Cancer Research, 58, 1909.
40. Perry P.J., Gowan S.M., Reszka A.P., Polucci P., Jenkins T.C., Kelland L.R., Neidle S. (1998a) 1,4-and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. Journal of Medicinal Chemistry, 41, 3253.
41. Perry P.J., Reszka A.P., Wood A.A., Read M.A., Gowan S.M., Dosanjh H.S., Trent J.O., Jenkins T.C., Kelland L.R., Neidle S. (1998b) Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones. Journal of Medicinal Chemistry, 41, 4873.
42. Perry P.J., Read M.A., Davies R.T., Gowan S.M., Reszka A.P., Wood A.A., Kelland, L.R., Neidle S. (1999) 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase. Journal of Medicinal Chemistry, 42, 2679.
43. Pitts A.E., Corey D.R. (1998) Inhibition of human telomerase by 2′-o-methyl-RNA. Proceedings of the National Academy of Science, USA, 95, 11549.
44. Pitts A.E., Corey D.R. (1999) The telomerase challenge - an unusual problem in drug discovery. Drug Discovery Today, 4, 155.
45. Raymond E., Sun D., Chen S.-F., Windle B., Von Hoff D.D. (1996) Agents that target telomerase and telomeres. Current Opinion in Biotechnology, 1, 583.
46. Raymond E., Sun D., Izbicka F., Mangold G., Silvas F., Windle B., Sharma S., Soda H., Laurence R., Davidson K., Von Hoff D.D. (1999) A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay. British Journal Cancer, 80, 1332.
47. Sharma S., Raymond E., Soda S., Sun D., Hilsenbeck S.G., Sharma A., Izbicka E., Windle B., Von Hoff D.D. (1997) Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Annals of Oncology, 8, 1063.
48. Simmons C.G., Pitts A.E., Mayfield L.D., Shay J.W., Corey D.R. (1997) Synthesis and membrane permeability of PNA-peptide conjugates. Bioorganic & Medical Chemistry Letters, 7, 3001.
49. Smith S., Giriat I., Schmitt A., de Lange T. (1998) Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science, 282, 1484.
50. Sun D., Hurley L.H., Von Hoff D.D. (1998) Telomerase assay using biotinylated-primer extension and magnetic separation of the products. Cancer Research Techniques, 23, 1046.
51. Sun D., Thompson B., Gathers B.E., Salazar M., Kerwin S.M., Trent J.O., Jenkins T.C., Neidle S., Hurley L.H. (1997) Inhibition of human telomerase by a G-quadruplex-interactive compound. Journal of Medicinal Chemistry, 40, 2113.
52. Togashi K.-I., Kakeya H., Morishita M., Song Y.-X., Osada H. (1998) Inhibition of human telomerase activity by alter-perylenol. Oncology Research, 10, 449.
53. Wan S.K.M., Fell P.L., Akhtar S. (1998) Synthetic 2′-O-Methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense, Nucleic Acid Drug Development, 8, 309.
54. Wang J., Xie L.Y., Allan S., Beach D., Hannon G.J. (1998) Myc activates telomerase. Genes & Development, 12, 1769.
55. Wang X., Wong S.C.H., Pan J., Tsao S.W., Fung K.H.Y., Kwong D.L.W., Sham J.S.T., Nicholls J.M. (1998) Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Research, 58, 5019.
56. Wheelhouse R.T., Sun D., Han H., Han F.X., Hurley L.H. (1998) Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA. Journal of the American Chemical Society, 120, 3261.
57. Wu K.-J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., Dalla-Favera R. (1999) Direct activation of TERT transcription by c-MYC. Nature Genetics, 21, 220.
58. Yokoyama Y., Takahashi Y, Shinohara A., Lian Z., Wan X., Niwa K., Tamaya T. (1998) Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Research, 58, 5406.
59. Zahler A.M., Williamson J.R., Cech T.R., Prescott D.M. (1991) Inhibition of telomerase by G-quartet DNA structures. Nature, 350, 718.
60. Zhu J., Wang H., Bishop J.M., Blackburn E.H. (1999) Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Cell Biology, 96, 3723.